Clinical Trials Logo

Hepatitis C clinical trials

View clinical trials related to Hepatitis C.

Filter by:

NCT ID: NCT02493855 Completed - Chronic Hepatitis C Clinical Trials

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

Start date: June 2015
Phase: Phase 2
Study type: Interventional

To evaluate the effect of ribavirin on second phase plasma hepatitis C virus (HCV) ribonucleic acid (RNA) decline in participants who receive ombitasvir/ABT-450/ritonavir and dasabuvir with full dose ribavirin, low dose ribavirin or without ribavirin for 2 weeks in treatment-naive HCV genotype (GT) 1a-infected adults.

NCT ID: NCT02487199 Completed - Clinical trials for Hepatitis C Virus (HCV)

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

Start date: September 30, 2015
Phase: Phase 3
Study type: Interventional

This study evaluates the efficacy and safety of ombitasvir/paritaprevir/ritonavir with or without dasabuvir in adults with hepatitis C virus (HCV) genotype 1a (GT1a) or genotype 4 (GT4) infection and with severe kidney impairment or end-stage kidney disease.

NCT ID: NCT02487030 Completed - Clinical trials for Hepatitis C Virus Infection

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Start date: September 7, 2015
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without ribavirin (RBV) in Egyptian adults with chronic genotype 4 hepatitis C virus (HCV) infection.

NCT ID: NCT02486406 Completed - Clinical trials for Chronic Hepatitis C Infection

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

ZIRCON
Start date: October 28, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV) in Hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4)-infected pediatric participants of ≥ 3 to 17 years of age.

NCT ID: NCT02483156 Completed - Hepatitis c Clinical Trials

Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection

Start date: July 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Two Groups of Genotype 4 HCV Patients will participate through open-label randomized Study comparing Sofosbuvir tablet Plus Ribavirin tablet (Part A) versus single Dose (2 tablets) of EHCV containing Sofosbuvir, Ribavirin, and Natural anti-hemolytic (B) evaluating the safety and efficacy for both arms. Sponsor: Wadi El Nil Hospital Study Centers Planned: Approximately 2 sites in Egypt

NCT ID: NCT02482077 Completed - Clinical trials for Chronic Hepatitis C Infection

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients

Start date: January 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with HCV genotypes 2 infection.

NCT ID: NCT02480712 Completed - Clinical trials for Hepatitis C Virus Infection

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

ASTRAL-5
Start date: July 1, 2015
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in participants with chronic HCV infection who were coinfected with HIV-1.

NCT ID: NCT02480686 Completed - Clinical trials for Chronic Hepatitis C Infection

Neutrino Regimen for Treatment-experienced HCV GT1 Patients

Start date: January 2015
Phase: Phase 4
Study type: Interventional

This study will evaluate the efficacy and safety of NEUTRINO regimen in Chinese chronic HCV genotype 1b treatment-experienced patients.

NCT ID: NCT02480387 Completed - Clinical trials for Treatment of Hepatitis C

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

Start date: May 2015
Phase: Phase 2
Study type: Interventional

Target Population: Hepatitis C Treatment Naïve, non-cirrhotic, Chronic genotype 1 hepatitis C virus (HCV) infected adults that are co-infected with human immunodeficiency virus (HIV)-1and have HCV RNA < 6 x106 IU/mL Duration of Subjects will be treated for 8 weeks and followed for 24 weeks post- Treatment: treatment

NCT ID: NCT02480166 Completed - PT-NANBH Clinical Trials

Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6

Start date: June 2015
Phase: Phase 4
Study type: Interventional

The primary objectives of this study are to describe the efficacy of: 1. 8-week treatment of SOF/LED for treatment-naïve, non-cirrhotic, HCV genotype 6 2. 12-week treatment of SOF/LED for all other HCV-6 populations